Photo taken from Paolo Tarantino/Twitter
Nov 19, 2023, 17:20
Paolo Tarantino: More important than ever to perform NGS/ctDNA to select the best 2L treatment after CDK4/6i
Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on X/Twitter:
“Capivasertib is now approved in combo with fulvestrant for pts with pretreated ER+/HER2- MBC whose tumor has an alteration in PIK3CA, AKT1 or PTEN (approx 40%).
More important than ever to perform NGS/ctDNA to select the best 2L treatment after CDK4/6i.”
For more information click here.
Source: Paolo Tarantino/Twitter